Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValve® devices: Results from the FRANCE 2 Registry. Issue 3 (18th February 2015)

• Record Type: Journal Article
• Authors: Mouillet, Gauthier; Lellouche, Nicolas; Yamamoto, Masanori; Oguri, Atsushi; Dubois‐Rande, Jean‐Luc; Van Belle, Eric; Gilard, Martine; Laskar, Marc; Teiger, Emmanuel
• Is Part Of: Catheterization and cardiovascular interventions. Volume 86:Issue 3(2015:Sep. 01)
• Page Start: E158
• Page End: E166
• Publication Date: 2015-02-18
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.25818
• Languages: English
• ISSNs: 1522-1946

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ccd25818-sec-0001" sec-type="section"> <title>Aims</title> <p>Permanent pacemaker (PPM) implantation following high‐degree atrioventricular block is frequently required after transcatheter aortic valve implantation (TAVI) using CoreValve<sup>®</sup>. Recent improvement of the delivery system (CoreValve Accutrak<sup>®</sup>) aimed to ease delivery and reduce the PPM rate. Our study evaluated the incidences of PPM implantation following use of CoreValve<sup>®</sup> or CoreValve Accutrak<sup>®</sup>and the clinical outcome of these patients.</p> </sec> <sec id="ccd25818-sec-0002" sec-type="section"> <title>Methods and results</title> <p>A total of 883 patients (82 ± 7 years; 41.3% female) with severe symptomatic aortic stenosis and self‐expanding bioprosthesis implantation were included between January 2010 and October 2011 in 29 centers from the FRANCE 2 Registry. Follow‐up data were available in 833 patients. CoreValve<sup>®</sup> and CoreValve Accutrak<sup>®</sup> were used in 343 (41.2%) and 490 (58.8%) patients, respectively. During a mean follow‐up of 242 ± 179 days, all‐cause mortality was similar in patients with versus without PPM implantation (16.3 vs. 16.9%, <italic>P</italic> = 0.832).There was no significant difference in the PPM incidence in CoreValve<sup>®</sup> and CoreValve Accutrak<sup>®</sup>patients (30.4% vs. 27.5%, <italic>P</italic> = 0.846).</p> </sec> <sec id="ccd25818-sec-0003" sec-type="section"> <title>Conclusion</title> <p>PPM implantation remained frequent after TAVI using CoreValve Accutrak<sup>®</sup>. All‐cause mortality was similar in patients with or without PPM implantation. The new device failed to show a significant decrease in PPM implantation incidence after TAVI. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>